These agreements include a grant by Genentech to Amgen of a license for multiple antibodies relating in part to methods of producing immunoglobulins. Financial details of the license agreements were not disclosed.
Amgen also recently announced that it investing over $1 billion in a new manufacturing and process development facility in Cork, Ireland.
The new Irish facility is part of a general trend of expansion and inward investment for the company which is also expanding its existing R&D operations at sites in the US including Cambridge, Massachusetts, San Francisco and Seattle, adding a manufacturing facility in Puerto Rico, and is planning to build a new development center in Uxbridge, UK.